Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/FXYD3_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FXYD3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FXYD3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FXYD3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FXYD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/FXYD3_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/FXYD3_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FXYD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FXYD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FXYD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200064912 | Lung | AIS | regulation of sodium ion transmembrane transporter activity | 16/1849 | 58/18723 | 1.09e-04 | 2.57e-03 | 16 |
GO:000202811 | Lung | AIS | regulation of sodium ion transport | 21/1849 | 90/18723 | 1.44e-04 | 3.13e-03 | 21 |
GO:003241211 | Lung | AIS | regulation of ion transmembrane transporter activity | 42/1849 | 267/18723 | 1.65e-03 | 1.89e-02 | 42 |
GO:002289811 | Lung | AIS | regulation of transmembrane transporter activity | 43/1849 | 278/18723 | 2.04e-03 | 2.24e-02 | 43 |
GO:001095912 | Lung | AIS | regulation of metal ion transport | 58/1849 | 406/18723 | 2.63e-03 | 2.67e-02 | 58 |
GO:003240911 | Lung | AIS | regulation of transporter activity | 45/1849 | 310/18723 | 5.54e-03 | 4.71e-02 | 45 |
GO:003241221 | Lung | AAH | regulation of ion transmembrane transporter activity | 19/613 | 267/18723 | 1.33e-03 | 3.62e-02 | 19 |
GO:002289821 | Lung | AAH | regulation of transmembrane transporter activity | 19/613 | 278/18723 | 2.11e-03 | 4.61e-02 | 19 |
GO:190230516 | Oral cavity | EOLP | regulation of sodium ion transmembrane transport | 17/2218 | 68/18723 | 2.00e-03 | 1.28e-02 | 17 |
GO:190230517 | Oral cavity | NEOLP | regulation of sodium ion transmembrane transport | 16/2005 | 68/18723 | 1.84e-03 | 1.26e-02 | 16 |
GO:000202813 | Oral cavity | NEOLP | regulation of sodium ion transport | 18/2005 | 90/18723 | 6.48e-03 | 3.33e-02 | 18 |
GO:20006499 | Oral cavity | NEOLP | regulation of sodium ion transmembrane transporter activity | 13/2005 | 58/18723 | 7.35e-03 | 3.71e-02 | 13 |
GO:00109598 | Oral cavity | NEOLP | regulation of metal ion transport | 59/2005 | 406/18723 | 9.36e-03 | 4.44e-02 | 59 |
GO:000202810 | Prostate | BPH | regulation of sodium ion transport | 25/3107 | 90/18723 | 5.18e-03 | 2.43e-02 | 25 |
GO:190230514 | Prostate | BPH | regulation of sodium ion transmembrane transport | 20/3107 | 68/18723 | 5.92e-03 | 2.73e-02 | 20 |
GO:000202812 | Prostate | Tumor | regulation of sodium ion transport | 26/3246 | 90/18723 | 4.54e-03 | 2.24e-02 | 26 |
GO:190230515 | Prostate | Tumor | regulation of sodium ion transmembrane transport | 20/3246 | 68/18723 | 9.64e-03 | 4.10e-02 | 20 |
GO:20006496 | Stomach | GC | regulation of sodium ion transmembrane transporter activity | 10/1159 | 58/18723 | 2.73e-03 | 2.52e-02 | 10 |
GO:19023056 | Stomach | GC | regulation of sodium ion transmembrane transport | 11/1159 | 68/18723 | 2.89e-03 | 2.61e-02 | 11 |
GO:00109594 | Stomach | GC | regulation of metal ion transport | 39/1159 | 406/18723 | 4.34e-03 | 3.58e-02 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FXYD3 | SNV | Missense_Mutation | | c.292G>C | p.Gly98Arg | p.G98R | Q14802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A2BK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
FXYD3 | SNV | Missense_Mutation | | c.203N>G | p.Phe68Cys | p.F68C | Q14802 | protein_coding | deleterious(0.01) | possibly_damaging(0.753) | TCGA-C8-A26Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
FXYD3 | SNV | Missense_Mutation | novel | c.310G>T | p.Val104Phe | p.V104F | Q14802 | protein_coding | deleterious(0) | possibly_damaging(0.868) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FXYD3 | SNV | Missense_Mutation | novel | c.323T>C | p.Met108Thr | p.M108T | Q14802 | protein_coding | deleterious(0.04) | benign(0.03) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
FXYD3 | SNV | Missense_Mutation | novel | c.128C>T | p.Ala43Val | p.A43V | Q14802 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.915) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
FXYD3 | SNV | Missense_Mutation | novel | c.145C>T | p.Leu49Phe | p.L49F | Q14802 | protein_coding | tolerated(0.24) | probably_damaging(0.974) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FXYD3 | SNV | Missense_Mutation | novel | c.257N>A | p.Pro86His | p.P86H | Q14802 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FXYD3 | SNV | Missense_Mutation | | c.274N>T | p.His92Tyr | p.H92Y | Q14802 | protein_coding | tolerated(0.17) | benign(0.013) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FXYD3 | SNV | Missense_Mutation | novel | c.257N>A | p.Pro86His | p.P86H | Q14802 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
FXYD3 | SNV | Missense_Mutation | novel | c.248A>C | p.Lys83Thr | p.K83T | Q14802 | protein_coding | deleterious(0.02) | probably_damaging(0.976) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |